ROIV Stock Overview
A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Roivant Sciences Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$11.57 |
| 52 Week High | US$13.24 |
| 52 Week Low | US$8.25 |
| Beta | 1.25 |
| 11 Month Change | -2.36% |
| 3 Month Change | 9.46% |
| 1 Year Change | -7.81% |
| 33 Year Change | 23.74% |
| 5 Year Change | n/a |
| Change since IPO | 11.25% |
Recent News & Updates
Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22
Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Recent updates
Statutory Earnings May Not Be The Best Way To Understand Roivant Sciences' (NASDAQ:ROIV) True Position
Aug 22Roivant Sciences: Inherently Risky Business Model, But Track Record Impresses
Aug 22Roivant Sciences: Executing On Huge Buyback Program With More To Come
Jun 02Roivant Sciences: $7bn Televant Sale Sets It Up For Long-Term Success
Mar 18We Believe Roivant Sciences' (NASDAQ:ROIV) Earnings Are A Poor Guide For Its Profitability
Feb 21These Analysts Just Made A Decent Downgrade To Their Roivant Sciences Ltd. (NASDAQ:ROIV) EPS Forecasts
Nov 15Are Investors Undervaluing Roivant Sciences Ltd. (NASDAQ:ROIV) By 21%?
Apr 26Broker Revenue Forecasts For Roivant Sciences Ltd. (NASDAQ:ROIV) Are Surging Higher
Nov 22Newsflash: Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Have Been Trimming Their Revenue Forecasts
Sep 29Roivant Sciences Ltd. (NASDAQ:ROIV) Analysts Are Reducing Their Forecasts For This Year
Aug 21Roivant Sciences GAAP EPS of -$0.48, revenue of $4.32M
Aug 15Shareholder Returns
| ROIV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.9% | -4.0% | 0.6% |
| 1Y | -7.8% | 18.1% | 32.1% |
Return vs Industry: ROIV underperformed the US Biotechs industry which returned 16.5% over the past year.
Return vs Market: ROIV underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| ROIV volatility | |
|---|---|
| ROIV Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ROIV has not had significant price volatility in the past 3 months.
Volatility Over Time: ROIV's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 908 | Matt Gline | roivant.com |
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases.
Roivant Sciences Ltd. Fundamentals Summary
| ROIV fundamental statistics | |
|---|---|
| Market cap | US$8.70b |
| Earnings (TTM) | US$4.74b |
| Revenue (TTM) | US$158.30m |
1.8x
P/E Ratio54.0x
P/S RatioIs ROIV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ROIV income statement (TTM) | |
|---|---|
| Revenue | US$158.30m |
| Cost of Revenue | US$523.34m |
| Gross Profit | -US$365.03m |
| Other Expenses | -US$5.10b |
| Earnings | US$4.74b |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 6.40 |
| Gross Margin | -230.59% |
| Net Profit Margin | 2,991.76% |
| Debt/Equity Ratio | 5.5% |
How did ROIV perform over the long term?
See historical performance and comparison